Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-6238-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD263 (TRAIL-R3) Monoclonal Antibody (DJR3), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The DJR3 monoclonal antibody reacts with human Decoy receptor 1 (DcR1), a glycophospholipid-anchored cell surface protein also known as TRAIL-R3, TRID, and LIT. DcR1 has an extracellular TRAIL binding domain and lacks the cytoplasmic death domain (DD) shared by several members of the TNF receptor superfamily. DcR1, along with DcR2, protects cells from TRAIL-mediated cytotoxicity. DcR1 binds to TRAIL and inhibits binding of TRAIL to DR4 or DR5. DcR1 is expressed broadly in many normal tissues at low level, but not in most tumors. Overexpression of DcR1 attenuates TRAIL-induced apoptosis.
- Conjugate
- Yellow dye
- Antibody clone number
- DJR3
- Concentration
- 5 µL/Test
Submitted references MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS
PloS one 2013;8(2):e56817
PloS one 2013;8(2):e56817
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
Hanada K, Wang QJ, Inozume T, Yang JC
Blood 2011 May 5;117(18):4816-25
Blood 2011 May 5;117(18):4816-25
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S
BMC musculoskeletal disorders 2010 Aug 27;11:192
BMC musculoskeletal disorders 2010 Aug 27;11:192
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY
Cancer research 2008 Jul 1;68(13):5335-44
Cancer research 2008 Jul 1;68(13):5335-44
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of human CD263-transfected cells with Mouse IgG1 kappa Isotype Control PE (Product # 12-4714-81) (open histogram) or Anti-Human CD263 (TRAIL-R3) PE (filled histogram). Total viable cells were used for analysis.
- Conjugate
- Yellow dye
